Skip to main content

Table 2 CSF Analysis on Weekly 50 mg IT Trastuzumab

From: Intrathecal trastuzumab: immunotherapy improves the prognosis of leptomeningeal metastases in HER-2+ breast cancer patient

Week 1 2 3 4
Protein (g/L) 31 52a 50a 68a
RBC (/cmm3) 519 74 15 <1
WBC (/cmm3) <1 3 2 <1